Skip to main content
OpenTrials

Clinical trial condition

Hepatitis C Virus Infection

Explore clinical trials studying Hepatitis C Virus Infection. Study availability and eligibility vary by location and protocol.

79 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Hepatitis C Virus Infection trial results

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection

NCT02413593

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +15 more
Locations
  • Calgary, Alberta, Canada
  • Edmonton, Alberta, Canada
  • Edmonton, Alberta, Canada
  • Vancouver, British Columbia, Canada
View all 15 locations
View Trial Details
Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

NCT02480712

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Birmingham, Alabama, United States
  • Los Angeles, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
View all 15 locations
View Trial Details
Completed

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

NCT02722837

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Krasnoyarsk Regional Center of AIDS Prevention Krasnoyarsk, Russia
  • Central Research Institute of Epidemiology Moscow, Russia
  • Central Scientific-Research Institute of Epidemiology Moscow, Russia
  • City Clinical Hospital # 24 Moscow, Russia
View all 15 locations
View Trial Details
Completed

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection

NCT02220998

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +12 more
Locations
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Los Angeles, California, United States
  • Los Angeles, California, United States
View all 51 locations
View Trial Details
Completed

Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

NCT02822794

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Ehime, Japan
  • Hiroshima, Japan
  • Ichikawa-shi, Japan
  • Iruma-gun, Japan
View all 18 locations
View Trial Details
Completed

Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant

NCT02781571

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Hospital Clínic de Barcelona Barcelona, Spain
  • Hospital Universitari Vall d'Hebron Barcelona, Spain
  • Reina Sofía University Hospital Córdoba, Spain
  • Hospital General Universitario Gregorio Maranon Madrid, Spain
View all 15 locations
View Trial Details

Related conditions